ArticlemBio2019
Differences in the Binding Affinity of an HIV-1 V2 Apex-Specific Antibody for the SIV
Open access · goldAbstract read
In one paragraph
Article in mBio, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 20 citations in OpenAlex.
- Genotypic and phenotypic characteristics of CXCR4-using transmitted/founder HIV-1 envelope glycoproteins.Journal of virology · 2026Article
- The RV144 Trial Might Still Yield Useful Information.Current HIV research · 2026Review
- Functional Activity of HIV-1 bNAbs Across Diverse Strains is Driven by Binding Site and Can be Enhanced Through Fc Engineering.bioRxiv : the preprint server for biology · 2025Article
- Molecular parameters governing antibody FcγR signaling and effector functions in the context of HIV envelope.Cell reports · 2025Article
- Viral glycoprotein-mediated entry and antibody-mediated immunity in HIV-1 and SARS-CoV-2 infection.Frontiers in immunology · 2025Review
- Potent antibody-dependent cellular cytotoxicity of a V2-specific antibody is not sufficient for protection of macaques against SIV challenge.PLoS pathogens · 2024Article
- Article
- Antibody-dependent cellular cytotoxicity, infected cell binding and neutralization by antibodies to the SIV envelope glycoprotein.PLoS pathogens · 2023Article
- Cryo-EM structures of prefusion SIV envelope trimer.Nature structural & molecular biology · 2022Article
- Molecular insights into antibody-mediated protection against the prototypic simian immunodeficiency virus.Nature communications · 2022Article
- Antiviral Activities of HIV-1-Specific Human Broadly Neutralizing Antibodies Are Isotype-Dependent.Vaccines · 2022Article
- Structure dynamics of HIV-1 Env trimers on native virions engaged with living T cells.Communications biology · 2021Article
- SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise.Microorganisms · 2021Review
- Contribution to HIV Prevention and Treatment by Antibody-Mediated Effector Function and Advances in Broadly Neutralizing Antibody Delivery by Vectored Immunoprophylaxis.Frontiers in immunology · 2021Review
- An Automated Fluorescence-Based Method to Isolate Bone Marrow-Derived Plasma Cells from Rhesus Macaques Using SIVmac239 SOSIP.664.Molecular therapy. Methods & clinical development · 2020Article
- Recent insights into Fc-mediated effector responses to HIV-1.Current opinion in HIV and AIDS · 2020Review
- A new cell line for assessing HIV-1 antibody dependent cellular cytotoxicity against a broad range of variants.Journal of immunological methods · 2020Article
- Induction of Transient Virus Replication Facilitates Antigen-Independent Isolation of SIV-Specific Monoclonal Antibodies.Molecular therapy. Methods & clinical development · 2020Article
- Flow Cytometry Analysis of HIV-1 Env Conformations at the Surface of Infected Cells and Virions: Role of Nef, CD4, and SERINC5.Journal of virology · 2020Article
- V2-Specific Antibodies in HIV-1 Vaccine Research and Natural Infection: Controllers or Surrogate Markers.Vaccines · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Benjamin von BredowDepartment of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin, USA.ORCID 0000-0001-8924-2193
Raiees AndrabiDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, USA.
Michael GrunstDepartment of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin, USA.
Andres G GrandeaDepartment of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin, USA.
Khoa LeDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, USA.
Ge SongDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, USA.
Zachary T BerndsenInternational AIDS Vaccine Initiative Neutralizing Antibody Center, the Collaboration for AIDS Vaccine Discovery (CAVD) and Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery (CHAVI-ID), The Scripps Research Institute, La Jolla, California, USA.
Katelyn PorterDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, USA.
Jesper PallesenInternational AIDS Vaccine Initiative Neutralizing Antibody Center, the Collaboration for AIDS Vaccine Discovery (CAVD) and Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery (CHAVI-ID), The Scripps Research Institute, La Jolla, California, USA.ORCID 0000-0002-3270-1587
Andrew B WardInternational AIDS Vaccine Initiative Neutralizing Antibody Center, the Collaboration for AIDS Vaccine Discovery (CAVD) and Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery (CHAVI-ID), The Scripps Research Institute, La Jolla, California, USA.
Dennis R BurtonDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, USA.
David T EvansDepartment of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin, USA dtevans2@wisc.edu.ORCID 0000-0003-2498-6292
Scripps Research Institute · USUniversity of Wisconsin–Madison · US
Funding
WNPRC Supplemental Request for Nonhuman Primate Enclosures to Equip HIV/AIDS-Related Research FacilitiesP51OD011106 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI Dorota A. Grejner-Brzezinska · 2012 to 2026
$150.7MSupport Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI CRISPIN, MAX · 2012 to 2018
$131.5MAntibody Effector Function in Protection Against HIV-1R37AI055332 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2009 to 2018
$9.7MSustained antibody delivery for durable suppression of immunodeficiency virus replicationR01AI121135 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI David T Evans · 2015 to 2026
$6.9MKIR and MHC Class I Immunogenetics in SIV InfectionR37AI095098 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI David T Evans · 2019 to 2026
$5.6MAssessing ADCC and Fc-mediated Protection against HIVR01AI148379 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI EVANS, DAVID T, FINZI, ANDRES · 2019 to 2023
$3.8MANTIBODY EFFECTOR FUNCTION IN PROTECTION AGAINST HIV-1R01AI055332 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2003 to 2007
$3.8MKIR and MHC Class I Immunogenetics in SIV InfectionR01AI095098 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI EVANS, DAVID T · 2012 to 2016
$2.7MLentiviral Resistance to TetherinR01AI098485 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI EVANS, DAVID T · 2012 to 2016
$2.2MNIAID NIH HHS R01 AI055332NIAID NIH HHS R01 AI095098NIAID NIH HHS R01 AI098485NIAID NIH HHS R01 AI121135NIAID NIH HHS R01 AI148379NIAID NIH HHS R37 AI055332NIAID NIH HHS R37 AI095098NIAID NIH HHS UM1 AI100663NIH HHS P51 OD011106
Abstract
As a consequence of their independent evolutionary origins in apes and Old World monkeys, human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency viruses of the SIV
Indexed as
Antibody-Dependent Cell CytotoxicityNeutralization TestsAntibodies, NeutralizingCell LineGlycoproteinsHIV AntibodiesHumansProtein BindingSimian Immunodeficiency VirusViral Envelope ProteinsAntibodies, NeutralizingGlycoproteinsHIV AntibodiesViral Envelope ProteinsADCCantibody functionhuman immunodeficiency virusneutralizing antibodiessimian immunodeficiency virus
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.